The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-06. Anything still debated is marked as such rather than presented as settled.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
While the presence of ethyl carbamate is not a sensory wine fault, the compound is a suspected carcinogen which is subjected to regulation in many countries. The compound is produced from the degradation of the amino acid arginine which is present in both grape must and released in the wine through the autolysis of dead yeast cells. While the use of urea as a source of yeast assimilable nitrogen (no longer legal in most countries) was the most common cause of ethyl carbamate in wine, both O. oeni and L. buchneri have been known to produce carbamyl phosphate and citrulline which can be precursors to ethyl carbamate formation. L. hilgardii, one of the "ferocious Lactobacillus" species, has also been suspected of contributing to ethyl carbamate production. In the United States, the Alcohol and Tobacco Tax and Trade Bureau has established a voluntary target limit of ethyl carbamate in wine to less than 15 μg/L for table wines and less than 60 μg/L for dessert wines. Biogenic amines have been implicated as a potential cause of red wine headaches. In wine, histamine, cadaverine, phenylethylamine, putrescine, and tyramine have all been detected. These amines are created by the degradation of amino acids found in grape must and left over from the breakdown of dead yeast cells after fermentation. Most LAB have the potential to create biogenic amines, even some strains of O. oeni, but high levels of biogenic amines are most often associated with species from the Lactobacillus and Pediococcus genera.
After site-specific phosphorylation by CK1δ, the stability of PER2 is increased and half-life of PER2 is expanded. Furthermore, PER2 stability can be influenced by CK1δ T344A mutation and site-specific phosphorylation of CK1δ at Thr-347 by other intracellular kinases.
==== 2013 resignation ==== In November 2013, Lad resigned from the Karnataka cabinet following allegations relating to illegal mining involving V. S. Lad & Sons, a company associated with his family. Contemporary reports stated that the company had been accused of illegal extraction and supply/export of iron ore. Lad said he resigned to avoid embarrassment to the Congress government and described his decision as a moral one. The resignation followed scrutiny of mining activity in the Ballari region and allegations concerning the classification of the company's mining lease. Reporting at the time also noted that the Karnataka Lokayukta had raised allegations concerning the company's mining activities.
On Thursday, February 1, 1866, Mary Baker Eddy, then known as Mary Patterson, fell on the ice in Lynn, Massachusetts. She had been on the way to a Good Templars meeting, an organization supporting the temperance movement, with friends from the organization. After her fall, the Lynn Reporter wrote that she was "in an insensible condition" and had internal injuries, and the notes of Dr. Alvin M. Cushing, a homeopathic doctor, who was called to the scene, state that he found Eddy "partially unconscious, semi-hysterical and complaining by word and action of severe pain in the back of her head and neck." She was taken to the nearest house, that of Samuel M. Bubier the future mayor of Lynn, and spent the night there. Cushing attended to her multiple times that day and during the night, which Gill writes "indicates that he considered the accident serious," and he gave orders that homeopathic medicine be continually given her at intervals of every half hour when she was awake while he was not present. Cushing later told Sibyl Wilbur that Eddy "was taken up unconscious and remained unconscious during the night" and that he thought she was "suffering from a concussion, and possible spinal dislocation." The next morning Eddy asked to be taken to her home in Swampscott, which Cushing arranged for against his own professional advice. In order to dull the pain of moving, Cushing gave Eddy "one-eighth of a grain of morphine" (a common painkiller at the time) according to his notes from the period.
==== Maintenance of the secret budget ==== During the electoral campaign, Lula repeatedly criticized the practice of the National Congress of allocating an increasingly relevant portion of the Union Budget to rapporteur's amendments, which critics called the secret budget, due to the lack of transparency regarding the amounts of each transfer and the names of the parliamentarians involved, and which was used by the Bolsonaro government to gather political support in parliament. After the election, Lula used his influence with the Supreme Federal Court to obtain a decision declaring the secret budget unconstitutional, by a narrow majority. At the time, the president of the Chamber of Deputies, Arthur Lira, alleged that he had seen Lula's interference in the vote of Ricardo Lewandowski, who after his retirement was invited to join the government as Minister of Justice. Despite the declaration of unconstitutionality, the National Congress continued in 2023 and 2024 with the same level of control over the budget, without transparency, replacing rapporteur's amendments with committee amendments and Pix amendments. In 2024, the non-transparent amendments will pay almost 25 billion reais.
Sources: en.wikipedia.org
== Interactions == Bempedoic acid does not interact with the cytochrome P450 enzyme system in the liver and only weakly inhibits the transporter proteins SLCO1B1, SLCO1B3 and SLC22A7 (the latter possibly being responsible for the increase of uric acid in the blood, and therefore the adverse effect gout). Despite this, the drug increases blood levels of statins. The effect is most pronounced with simvastatin and pravastatin, whose AUC is increased about twofold. No other clinically relevant interactions have been found in studies.
Calcined uranium yellowcake, as produced in many large mills, contains a distribution of uranium oxidation species in various forms ranging from most oxidized to least oxidized. Particles with short residence times in a calciner will generally be less oxidized than those with long retention times or particles recovered in the stack scrubber. Uranium content is usually referenced to U3O8, which dates to the days of the Manhattan Project when U3O8 was used as an analytical chemistry reporting standard. Phase relationships in the uranium-oxygen system are complex. The most important oxidation states of uranium are uranium(IV) and uranium(VI), and their two corresponding oxides are, respectively, uranium dioxide (UO2) and uranium trioxide (UO3). Other uranium oxides such as uranium monoxide (UO), diuranium pentoxide (U2O5), and uranium peroxide (UO4·2H2O) also exist. The most common forms of uranium oxide are triuranium octoxide (U3O8) and UO2. Both oxide forms are solids that have low solubility in water and are relatively stable over a wide range of environmental conditions. Triuranium octoxide is (depending on conditions) the most stable compound of uranium and is the form most commonly found in nature. Uranium dioxide is the form in which uranium is most commonly used as a nuclear reactor fuel. At ambient temperatures, UO2 will gradually convert to U3O8. Because of their stability, uranium oxides are generally considered the preferred chemical form for storage or disposal.
The beef hormone controversy or beef hormone dispute is a disagreement over the use of growth hormones in beef production. In 1989, the European Communities banned the import of meat that contained artificial beef growth hormones, although they were approved for use in the United States. In 2003 estradiol-17β was permanently banned, while provisionally banning five others. World Trade Organization (WTO) rules permit such bans, but only where a signatory presents valid scientific evidence that the ban is a health and safety measure. Canada and the United States opposed this ban, taking the EU to the WTO Dispute Settlement Body. In 1997, the WTO Dispute Settlement Body ruled against the EU. It remains one of the most intractable agricultural trade controversies since the establishment of the WTO. It is not the same as the UK–EU dispute over bovine spongiform encephalopathy, although both have been termed the "beef war".
Jürgen Sundermann (28 May 1991 – 30 June 1993) Bernd Stange (1 July 1993 – 21 February 1994) Jürgen Sundermann (22 February 1994 – 8 April 1994) Damian Halata (9 April 1994 – 30 June 1994) Tony Woodcock (1 July 1994 – 30 October 1994) August "Gustl" Starek (31 October 1994 – 30 May 1996) Damian Halata (1 June 1996 – 30 June 1996) Sigfried "Siggi" Held (1 July 1996 – 7 October 1997) Damian Halata (8 October 1997 – 30 June 1998) Hans-Ulrich "Uli" Thomale (1 July 1998 – 28 March 1999) Dragoslav Stepanović (29 March 1999 – 29 August 1999) Joachim Steffens (30 August 1999 – 22 July 2001) Hans-Jürgen "Dixie" Dörner (23 July 2001 – 26 March 2003) Detlef Schößler (27 March 2003 – 3 June 2003) Hermann Andreev (24 June 2003 – 19 March 2004) Michael Breitkopf and Jörg Engelmann (20 March 2004 – 22 April 2004) Mike Sadlo (23 April 2004 – 30 June 2004) – Player/manager 1. FC Lok Leipzig
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.